Evaluation of an assay for serum 1,5-anhydroglucitol (GlycoMark™) and determination of reference intervals on the Hitachi 917 analyzer

Nowatzke, William; Sarno, Mark J.; Birch, Nathan C.; Stickle, Douglas F.; Eden, Tanya; Cole, Thomas G.

doi:10.1016/j.cccn.2004.08.013

Cited by 44 publications

(57 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First, as expected, the 1,5-AG concentration was strongly inversely correlated with the A1C level in diabetic patients from both groups. The influence of sex and age on 1,5-AG levels was observed previously in control subjects (14,18) but, as with our data, not in the diabetic study groups, as reported from other populations (18). The creatinine level did not influence plasma 1,5-AG concentration in these study groups: all three groups had normal creatinine levels.…”

supporting

confidence: 89%

“…The creatinine level did not influence plasma 1,5-AG concentration in these study groups: all three groups had normal creatinine levels. The mean level of 1,5-AG in the control group was slightly higher than that in an American reference population (14), which may be caused by different nutritional habits in the Polish population, especially higher consumption of cereal food.…”

mentioning

confidence: 58%

“…Serum and EDTA-plasma were obtained by spinning at 3,500 rpm and stored at Ϫ80°C. The 1,5-AG concentration was measured in EDTA-plasma samples with an enzymatic, colorimetric method using GlycoMark chemicals (Tomen America) by Nippon Kayaku Tokyo Co. (Tokyo, Japan) (14 RESULTS -Clinical characteristics of the study groups are presented in Table 1. Both diabetic groups were similar for traditional measures of metabolic control such as fasting glucose and A1C.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Clinical Application of 1,5-Anhydroglucitol Measurements in Patients with Hepatocyte Nuclear Factor-1α Maturity-Onset Diabetes of the Young

et al. 2008

View full text Add to dashboard Cite

OBJECTIVE -1,5-anhydroglucitol (1,5-AG) is a short-term marker of metabolic control in diabetes. Its renal loss is stimulated in hyperglycemic conditions by glycosuria, which results in a lowered plasma concentration. As a low renal threshold for glucose has been described in hepatocyte nuclear factor-1␣ (HNF-1␣) maturity-onset diabetes of the young (MODY), the 1,5-AG level may be altered in these patients. The purpose of this study was to assess the 1,5-AG levels in patients with HNF-1␣ MODY and in type 2 diabetic subjects with a similar degree of metabolic control. In addition, we aimed to evaluate this particle as a biomarker for HNF-1␣ MODY.RESEARCH DESIGN AND METHODS -We included 33 diabetic patients from the Polish Nationwide Registry of MODY. In addition, we examined 43 type 2 diabetic patients and 47 nondiabetic control subjects. The 1,5-AG concentration was measured with an enzymatic assay (GlycoMark). Receiver operating characteristic (ROC) curve analysis was used to evaluate 1,5-AG as a screening marker for HNF-1␣ MODY.RESULTS -The mean 1,5-AG plasma concentration in diabetic HNF-1␣ mutation carriers was 5.9 g/ml, and it was lower than that in type 2 diabetic patients (11.0 g/ml, P ϭ 0.003) and in nondiabetic control subjects (23.9 g/ml, P Ͻ 0.00005). The ROC curve analysis revealed 85.7% sensitivity and 80.0% specificity of 1,5-AG in screening for HNF-1␣ MODY at the criterion of Ͻ6.5 g/ml in patients with an A1C level between 6.5 and 9.0%.CONCLUSIONS -1,5-AG may be a useful biomarker for differential diagnosis of patients with HNF-1␣ MODY with a specific range of A1C, although this requires further investigation. However, the clinical use of this particle in diabetic HNF-1␣ mutation carriers for metabolic control has substantial limitations.

show abstract

supporting

confidence: 89%

mentioning

confidence: 58%

mentioning

confidence: 99%

See 1 more Smart Citation

Clinical Application of 1,5-Anhydroglucitol Measurements in Patients with Hepatocyte Nuclear Factor-1α Maturity-Onset Diabetes of the Young

et al. 2008

View full text Add to dashboard Cite

show abstract

“…In many cases, serum or plasma 1,5-AG levels were assayed by an enzymatic method using a series of enzymes including glucokinase and pyranose oxidase to remove interference and then produce colorimetrical product [13,24,25]. This method is sensitive and precise, but it can also be disadvantageous for its expensive multi-enzyme reagents.…”

Section: Introductionmentioning

confidence: 99%

“…This compound has been proposed and validated early in Japan [2][3][4][5][6][7] and recently in the US [8][9][10][11][12] as a marker for short-term glycemic control. The assay of 1,5-AG (GlycoMark TM ) was granted marketing clearance by the US Food and Drug Administration (FDA) in 2003, with the enzymatic method operated on Hitachi 917 chemistry analyzer [13].…”

Section: Introductionmentioning

confidence: 99%

Determination of glycemic monitoring marker 1,5-anhydroglucitol in plasma by liquid chromatography-electrospray tandem mass spectrometry

Li¹,

Heng²,

Wang³

et al. 2008

Journal of Chromatography B

View full text Add to dashboard Cite

A study on the association of serum 1,5‐anhydroglucitol levels and the hyperglycaemic excursions as measured by continuous glucose monitoring system among people with type 2 diabetes in China

Wang

Zhang

Wang

et al. 2012

Diabetes Metabolism Res

View full text Add to dashboard Cite

BackgroundBlood glucose excursion is an important component of the glycaemic burden, but there are no indexes that can directly reflect them. The aim was to evaluate the values and significance of serum 1,5-anhydroglucitol (1,5-AG) in people with type 2 diabetes mellitus in China and to elucidate the relationship between 1,5-AG and traditional indexes of glycaemic excursions by continuous glucose monitoring.MethodsA total of 576 healthy adults and 292 patients were included, and their 1,5-AG, fasting blood glucose and postprandial blood glucose and glycated haemoglobin were measured. For the 34 patients, their mean blood glucose, standard deviation of blood glucose, mean amplitude of glucose excursion, mean of daily differences, low blood glucose M-value index and the area under the curve for blood glucose above 180 mg/dL were calculated by use of a continuous glucose monitoring system.ResultsSerum levels of 1,5-AG among healthy adults were 28.44 ± 8.76 µg/mL with a significant gender bias rather than age bias. The 1,5-AG levels in people with type 2 diabetes mellitus were 4.57 ± 3.71 µg/mL, which were lower than those seen in the healthy adults. There was a correlation between 1,5-AG and glycated haemoglobin, fasting blood glucose, and postprandial blood glucose (r = −0.251, −0.195 and −0.349, respectively; all had p < 0.05). The continuous glucose monitoring system demonstrated that 1,5-AG presents a negative correlation with mean blood glucose, standard deviation of blood glucose, mean amplitude of glucose excursion and mean of daily differences for 7 days and with the area under the curve for blood glucose above 180 mg/dL on the third, fourth and seventh days.Conclusions1,5-AG may serve as a marker of hyperglycaemia and 7-day hyperglycaemic excursions as well as being a useful adjunct to glycated haemoglobin for blood glucose monitoring in patients with diabetes. Copyright © 2012 John Wiley & Sons, Ltd.

show abstract

Evaluation of an assay for serum 1,5-anhydroglucitol (GlycoMark™) and determination of reference intervals on the Hitachi 917 analyzer

Cited by 44 publications

References 21 publications

Clinical Application of 1,5-Anhydroglucitol Measurements in Patients with Hepatocyte Nuclear Factor-1α Maturity-Onset Diabetes of the Young

Clinical Application of 1,5-Anhydroglucitol Measurements in Patients with Hepatocyte Nuclear Factor-1α Maturity-Onset Diabetes of the Young

Determination of glycemic monitoring marker 1,5-anhydroglucitol in plasma by liquid chromatography-electrospray tandem mass spectrometry

A study on the association of serum 1,5‐anhydroglucitol levels and the hyperglycaemic excursions as measured by continuous glucose monitoring system among people with type 2 diabetes in China

Contact Info

Product

Resources

About